UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer

JNCI : Journal of the National Cancer Institute, 2012-12, Vol.104 (23), p.1785-1795

2012

Volltextzugriff (PDF)

Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population

Journal of medical economics, 2020-01, Vol.23 (1), p.54-63

2020

Volltextzugriff (PDF)

Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide

American health & drug benefits, 2017-09, Vol.10 (6), p.296-303

2017

Volltextzugriff (PDF)

Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

Advances in therapy, 2020-01, Vol.37 (1), p.501-511

2020

Volltextzugriff (PDF)

Consideration of Potential Drug–Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer

American journal of therapeutics, 2019-05, Vol.26 (3), p.e422-e424

2019

Volltextzugriff (PDF)

Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide

Journal of managed care & specialty pharmacy, 2017-02, Vol.23 (2), p.225-235

2017

Volltextzugriff (PDF)

Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy

American health & drug benefits, 2017-05, Vol.10 (3), p.143-153

2017

Volltextzugriff (PDF)

Estimating the Size and Cost of the STD Prevention Services Safety Net

Public health reports (1974), 2015-11, Vol.130 (6), p.602-609

2015

Volltextzugriff (PDF)

PS1-30: Cost-Effectiveness Analysis of Screening for Kras and Braf Genetic Mutations in Metastatic Colorectal Cancer

Clinical medicine & research, 2011-11, Vol.9 (3-4), p.174-174

Behl, A.

2011

Volltextzugriff (PDF)

Children and labour supply

Applied economics letters, 2010-02, Vol.17 (3), p.251-255

Behl, Ajay Singh

2010

Volltextzugriff (PDF)

Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice

Urology Practice, 2017-05, Vol.4 (3), p.218-224

2017

Volltextzugriff (PDF)

Community-level incentives to increase the use of vaccination services in developing countries: An idea whose time has come?

Vaccine, 2010-08, Vol.28 (38), p.6123-6124

2010

Volltextzugriff (PDF)

Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection

Journal of comparative effectiveness research, 2015-11, Vol.4 (6), p.593-605

2015

Volltextzugriff (PDF)

PS1-65: Relationships Matter! Modeling Segregation and Social Networks to Evaluate Prevention Services for STDs

Clinical medicine & research, 2012-08, Vol.10 (3), p.169-169

2012

Volltextzugriff (PDF)

15457 Secukinumab significantly improves clinical and patient-reported outcomes up to 18 months of follow-up: Real-world evidence from a US psoriasis registry

Journal of the American Academy of Dermatology, 2020-12, Vol.83 (6), p.AB152-AB152

2020

Volltextzugriff (PDF)

PS3-47: Rural Health Research Initiative in the HMORN: A New Scientific Interest Group

Clinical medicine & research, 2013-09, Vol.11 (3), p.142-142

2013

Volltextzugriff (PDF)

PD37-04 STATINS AND ORAL TREATMENTS IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): REAL-WORLD OUTCOMES

The Journal of urology, 2017-04, Vol.197 (4), p.e675-e675

2017

Volltextzugriff (PDF)

CB2-05: Chemotherapy Treatment Patterns Among Advanced Colon Cancer Patients

Clinical medicine & research, 2012-08, Vol.10 (3), p.152-153

2012

Volltextzugriff (PDF)

Assessment of health care resource utilization (HRU) in patients with castration-resistant prostate cancer (CRPC)

Journal of clinical oncology, 2018-10, Vol.36 (30_suppl), p.89-89

2018

Volltextzugriff (PDF)

Prevalence of glucocorticoid use in prostate cancer patients

Journal of clinical oncology, 2016-01, Vol.34 (2_suppl), p.336-336

2016

Volltextzugriff (PDF)

Remdesivir induced bradycardia and QT prolongation: A rare side effect of a ubiquitous drug of the COVID -19 era

Journal of anaesthesiology, clinical pharmacology, 2022-01, Vol.38 (Suppl 1), p.S148-S149

2022

Volltextzugriff (PDF)

Cost of care for patients with metastatic castration-resistant prostate cancer initiating on docetaxel versus oral targeted therapies in the United States

Journal of clinical oncology, 2018-10, Vol.36 (30_suppl), p.88-88

2018

Volltextzugriff (PDF)

Costs of pre-hospice care among metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone + prednisone (ABI) and enzalutamide (ENZ)

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e16534-e16534

2017

Volltextzugriff (PDF)

Costs of skeletal-related events (SREs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with oral therapies

Journal of clinical oncology, 2017-05, Vol.35 (15_suppl), p.e16539-e16539

2017

Volltextzugriff (PDF)

Prostate-specific antigen (PSA) measurements' association with metastasis and mortality in patients with nmCRPC (non-metastatic castration resistant prostate cancer)

Journal of clinical oncology, 2018-05, Vol.36 (15_suppl), p.e17058-e17058

2018

Volltextzugriff (PDF)

1 – 25 von 72

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(57)
Mit Volltextzugriff
(60)

Publikationsform

Sprache

Englisch
(72)

Erscheinungsjahr

n.n

Thema

Science & Technology
(19)
Life Sciences & Biomedicine
(17)
Humans
(9)
Male
(7)
Health Care Sciences & Services
(6)
Pharmacology & Pharmacy
(6)
Middle Aged
(5)
United States
(5)
Aged
(4)
Female
(4)
Adult
(3)
Food
(3)
Mutation
(3)
Oncology
(3)
Retrospective Studies
(3)
Treatment Outcome
(3)
Antineoplastic Agents - Administration & Dosage
(2)
Antioxidants
(2)
Biological And Medical Sciences
(2)
Chemistry
(2)

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Cost-effectiveness analysis of screening for KRAS and BRAF mutations in metastatic colorectal cancer

Total cost of care for castration-resistant prostate cancer in a commercially insured population and a medicare supplemental insured population

Medication Adherence, Treatment Patterns, and Dose Reduction in Patients with Metastatic Castration-Resistant Prostate Cancer Receiving Abiraterone Acetate or Enzalutamide

Matching-Adjusted Indirect Comparison of the Efficacy of Apalutamide and Enzalutamide with ADT in the Treatment of Non-Metastatic Castration-Resistant Prostate Cancer

Consideration of Potential Drug–Drug Interactions in Selection of FDA-Approved Drugs Indicated for Prostate Cancer

Duration of Treatment in Prostate Cancer Patients Treated with Abiraterone Acetate or Enzalutamide

Assessment of Real-World Central Nervous System Events in Patients with Advanced Prostate Cancer Using Abiraterone Acetate, Bicalutamide, Enzalutamide, or Chemotherapy

Estimating the Size and Cost of the STD Prevention Services Safety Net

PS1-30: Cost-Effectiveness Analysis of Screening for Kras and Braf Genetic Mutations in Metastatic Colorectal Cancer

Children and labour supply

Assessment of Evidence-Based Standards in the Treatment of Advanced Prostate Cancer in a Community Practice

Community-level incentives to increase the use of vaccination services in developing countries: An idea whose time has come?

Comparative efficacy and safety of daclatasvir/asunaprevir versus IFN-based regimens in genotype 1b hepatitis C virus infection

PS1-65: Relationships Matter! Modeling Segregation and Social Networks to Evaluate Prevention Services for STDs

15457 Secukinumab significantly improves clinical and patient-reported outcomes up to 18 months of follow-up: Real-world evidence from a US psoriasis registry

PS3-47: Rural Health Research Initiative in the HMORN: A New Scientific Interest Group

PD37-04 STATINS AND ORAL TREATMENTS IN PATIENTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC): REAL-WORLD OUTCOMES

CB2-05: Chemotherapy Treatment Patterns Among Advanced Colon Cancer Patients

Assessment of health care resource utilization (HRU) in patients with castration-resistant prostate cancer (CRPC)

Prevalence of glucocorticoid use in prostate cancer patients

Remdesivir induced bradycardia and QT prolongation: A rare side effect of a ubiquitous drug of the COVID -19 era

Cost of care for patients with metastatic castration-resistant prostate cancer initiating on docetaxel versus oral targeted therapies in the United States

Costs of pre-hospice care among metastatic castration-resistant prostate cancer (mCRPC) patients treated with abiraterone + prednisone (ABI) and enzalutamide (ENZ)

Costs of skeletal-related events (SREs) in patients with metastatic castrate-resistant prostate cancer (mCRPC) treated with oral therapies

Prostate-specific antigen (PSA) measurements' association with metastasis and mortality in patients with nmCRPC (non-metastatic castration resistant prostate cancer)

Suchergebnisse filtern